

MANUFACTURERS OF PARENTERAL PRODUCTS
[CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: denischem401@gmail.com

10<sup>th</sup> August, 2022

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

Company Code No. 537536

Dear Sirs,

Sub: - Outcome of Board Meeting

- Submission of Un-audited Financial Results for the Quarter ended on 30th June, 2022

We refer to our letter dated 1<sup>st</sup> August, 2022 informing the date of Meeting of the Board of Directors of the Company, please note that the Board of Directors in their meeting held today, have taken on record the Un-audited Financial Results for the quarter ended on 30<sup>th</sup> June, 2022.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30<sup>th</sup> June, 2022 along with Limited Review Report thereon.

This is as per Regulation – 33 and other applicable provisions of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

for DENIS CHEM LAB LIMITED

HIMANSHU C. PATEL MANAGING DIRECTOR

(DIN: 00087114)

Encl: As above.





MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: denischem401@gmail.com

## STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON $30^{TH}$ JUNE, 2022

(Rs. in lakhs)

Particulars		Q	Previous Year ended on			
		30-06-2022	31-03-2022	30-06-2021	31-03-2022	
	(Refer Notes Below)	(Un-audited)	(Audited)	(Un-audited)	(Audited)	
1	Revenue from operations	3928.72	3777.44	3315.75	13655.65	
2	Other income	7.52	92.90	6.73	104.59	
3	Total Income (1+2)	3936.24	3870.34	3322.48	13760.24	
4	Expenses					
	a. Cost of Materials consumed	1964.15	2069.36	1560.89	6831.08	
	b.Purchases of stock-in-trade	240.68	155.90	55.48	400.75	
	c. Changes in inventories of finished goods, work-in-progress and stock-in- trade	80.12	(44.51)	159.53	2.58	
	d.Employee benefits expense	282.94	355.45	265.50	1173.99	
	e. Finance costs	17.24	10.52	23.61	75.64	
	f. Depreciation & amortisation expense	135.57	147.48	139.58	575.75	
	g.Other expenses	930.28	1025.67	893.06	3812.11	
	Total Expenses	3650.98	3719.87	3097.65	12871.90	
5	Profit before exceptional items and tax (3-4)	285.26	150.47	224.83	888.34	
6	Exceptional items	-		-		
7	Profit before tax (5-6)	285.26	150.47	224.83	888.34	
8	Tax expense:				, , , , , , , , , , , , , , , , , , , ,	
	Current tax	86.88	38.02	60.05	215.00	
	Deferred tax	(16.21)	18.17	3.57	47.04	
9	Profit for the period from continuing operations (7-8)	214.59	94.28	161.21	626.30	
10	Profit/(loss) from discontinuing operations before Tax	-	-			
11	Tax expense of discontinuing operations	-	-			
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-			
13	Profit for the period (9+12)	214.59	94.28	161.21	626.30	

REGD OFFICE & FACTORY: BLOCK NO. 457, VILLAGE: CHHATRAL, TAL: KALOL (N.G.) DIST: GANDHINAG TEL: +91 (2764) 233596, 233613 FAX: +91 (2764) 233896 WEB: www.denischemick.



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



75.49.5	Particulars	Quarter ended on			Previous Year ended
		30-06-2022 (Un-audited)	31-03-2022 (Audited)	30-06-2021 (Un-audited)	on 31-03-2022 (Audited)
14	Other Comprehensive Income				
	Items that will not be reclassified subsequently to profit or loss				
	Gain/(loss) on Remeasurement of defined benefit plan	•	-	=	(38.16)
	Income tax relating to items that will not be reclassified to Profit or loss	*	-	-	10.62
	Items that will be reclassified subsequently to profit or loss	=	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other Comprehensive Income, net of tax	•	-	-	(27.55)
15	Total Comprehensive Income for the period (13+14)	214.59	94.28	161.21	598.75
16	Paid-up equity shares capital (Face Value per share Rs.10)	1387.67	1387.67	1387.67	1387.67
17	Reserves excluding Revaluation Reserves				5257.46
18	Earnings Per Share of Rs.10 each (for continuing operations)		-		
	- Basic	1.55	0.68	1.16	4.51
	- Diluted	1.55	0.68	1.16	4.51
19	Earnings Per Share of Rs.10 each (for discontinued operations)				
	- Basic	•	-	-	
	- Diluted	-	-	•	•
20	Earnings Per Share of Rs10 each (for discontinued & continuing operations)				
	- Basic	1.55	0.68	1.16	4.51
	- Diluted	1.55	0.68	1.16	4.51



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: denischem401@gmail.com

#### Notes:

1	These Unaudited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules as amended from time to time. These financial results were reviewed by the audit committee and thereafter have been approved by the Board of Directors at its meeting held on Wednesday, 10 <sup>th</sup> August, 2022.
2	The Statutory Auditors have conducted limited review of these results and issued an unmodified opinion on the same.
3	The Company is operating only in one segment i.e. manufacturing and sales of Transfusion solution in Bottles. Hence there is no any additional disclosure to be made under Ind AS 108 Operating Segments.
4	The Company does not have any subsidiary/associate.
5	The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on 13 <sup>th</sup> November, 2020 and has invited suggestions from the stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the said code become effective including related rules framed thereunder to determine the financial impact are published.
6	The figures for quarter ended on 31 <sup>st</sup> March, 2022 are the balancing figures between the audited figures in respect of the full financial year ended on 31 <sup>st</sup> March, 2022 and the year to date figures up to the third quarter of the financial year 2021-22 which were subjected to limited review by the Statutory Auditors.
7	Figures, wherever required, are regrouped / rearranged.

For DENIS CHEM LAB LIMITED

Date: 10<sup>th</sup> August, 2022 Place: Ahmedabad SIN LAB CO

HIMANSHU C. PATEL MANAGING DIRECTOR (DIN: 00087114)

# H K Shah & Co. **CHARTERED ACCOUNTANTS**

Independent Auditor's Review Report on the unaudited standalone financial results of M/s. DENIS CHEM LAB LIMITED for the quarter ended on 30th June, 2022 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To The Board of Directors of **DENIS CHEM LAB LIMITED** 

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of **DENIS CHEM LAB LIMITED** ("the Company") for the quarter ended 30<sup>th</sup> June, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Statement").
- 2. This statement which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410,"Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

C& AG NO. WRO/510 FRN NO. 109583/W RBI UNIQUE CODE NO. 122900 Place: Ahmedabad AHMEDABAD

UDIN: 22014711AORWGY1484

hkshahandco@gmail.com www.hkshahandco.com

GSTIN 24AACFH1917R1Z6 | PAN AACFH1917R | FRN 109583W

079-27544995 / 27542785 +91-9909919785 +91-9714744995

Date: August 10, 2022

Mead Head Office

403+404 'SARAP' Building, Opp. Navjivan Press, Off Ashram Road, Nr. Income Tax, Ahmedabad - 380014

SHAH & CO

For H K SHAH & Co. Chartered Accountants

ACCOUNT Partner mbership Number:014711

FRN:109583W

CAKM Shah

Partner

Branch | Gujarat, Maharashtra, Tamil Nadu & Offices Uttar Pradesh